Abu Dhabi lures Eli Lilly, Oura, and Whoop in healthcare push
Mubadala Bio signed a deal with US drugmaker Eli Lilly during the Future Health Summit this week to package and distribute GLP-1 drugs locally.
Abu Dhabi is making a significant investment in healthcare by luring major players in the GLP-1 drug market and wearable technology industry. The UAE capital recently hosted the Future Health Summit, during which Mubadala Bio signed an agreement with US pharmaceutical giant Eli Lilly to package and distribute GLP-1 drugs locally. This comes after the UAE became the second country to register Lilly’s weight-loss pill, Foundayo, and an early market for Mounjaro.
In addition to its pharmaceutical endeavors, Abu Dhabi has also teamed up with wearable technology giants Whoop and Oura. The Department of Health has launched research projects in collaboration with these brands. Whoop will investigate whether continuous monitoring and coaching can help improve cholesterol levels in adults with obesity and hypertension, both prevalent issues in the Gulf region.
Meanwhile, Oura is launching Project Cradle, a two-year pilot program aiming to determine if its wearable ring can detect spontaneous preterm birth in high-risk pregnancies. This ambitious initiative will utilize Abu Dhabi’s clinical and genomic records.
Written by urgent.news from Semafor's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
